Roche's Alecensa passes Phase III NSCLC test

Roche (SIX:ROG; OTCQX:RHHBY) said Alecensa alectinib met the primary endpoint in the Phase III ALUR trial to treat anaplastic lymphoma kinase-positive non-small cell lung cancer. Alecensa significantly improved progression-free survival (PFS) vs. chemotherapy with pemetrexed or docetaxel in patients who progressed following treatment with one prior line of both platinum-based chemotherapy and Xalkori crizotinib.

The open-label study compared twice-daily 600 mg oral Alecensa to chemotherapy in 119 patients. Roche plans to publish ALUR's data this year...